“Having spent the final 10 years rising the genetic evaluation companies at a multi-billion greenback firm, I am excited by the great potential in Mission Bio’s industry-first multi-omics capabilities – each to speed up our understanding of most cancers and to allow novel cell and gene remedy improvement with biopharma companions,” mentioned Yan Zhang, CEO of Mission Bio. “We’re on the daybreak of one other unbelievable age of breakthroughs in bettering human well being. I’m honored to steer the Mission Bio crew in its subsequent part of hyper-growth and scale the corporate to fulfill its full potential.”
“Yan shares our imaginative and prescient for the facility of single-cell multi-omics to enhance affected person outcomes for advanced ailments like most cancers,” mentioned Charlie Silver, Mission Bio co-founder, and advisor. “She additionally brings a deep appreciation for the worth in main a world-class crew that may execute with precision, humility, and humanity. Yan’s expertise, imaginative and prescient, and confirmed monitor report are an excellent mixture for main Mission Bio into the longer term.”
Earlier than becoming a member of Thermo Fisher Scientific, Zhang led product administration and commercialization efforts for genetic evaluation options at Affymetrix, NuGEN Applied sciences, and Molecular Gadgets. Zhang holds a Ph.D. in Biochemistry from the Medical Faculty of Wisconsin and has devoted her profession to accelerating broad market entry of rising genomic applied sciences to advance translational analysis and scientific purposes in precision drugs.
“Yan spent the final decade rising the genomics enterprise for one of many world’s largest life sciences firms,” mentioned Robert Ghenchev, Senior Accomplice and Head of Novo Development and Mission Bio board member. “Throughout that point, she demonstrated a constant potential to efficiently commercialize modern new applied sciences — together with scientific NGS merchandise— into excessive development markets. With its skilled crew and distinctive know-how, Mission Bio has reached the tipping level that each one firms on this area hope to realize,” added Ghenchev. “I am unable to consider anybody higher suited to take Mission Bio into the following part of innovation and commercialization than Yan Zhang.”
Right now’s announcement follows various current developments for the corporate, together with a $70 million Collection C fundraise within the second half of 2020, rising use of its Tapestri Platform in peer-reviewed publications together with Nature and Nature Communications, and new partnerships to broaden the worldwide distribution and adoption of its Tapestri Platform in high-growth market segments.
To study extra about Mission Bio and the way the Tapestri Platform helps improve most cancers analysis and unlock pathways to new therapies, go to missionbio.com.
About Mission Bio
Mission Bio is a life sciences firm that accelerates discoveries and cures in oncology by equipping researchers with the instruments they should higher measure and predict our resistance and response to most cancers therapies. Mission Bio’s multi-omics method improves time-to-market for brand new therapeutics, together with modern cell and gene therapies that present new pathways to well being. Based in 2014, Mission Bio has secured funding from Novo Development, Cota Capital, Agilent Applied sciences, Mayfield Fund, and others.
The corporate’s Tapestri platform provides researchers across the globe the facility to interrogate each molecule in a cell collectively, offering a complete understanding of exercise from a single pattern. Tapestri is the one commercialized multi-omics platform able to analyzing DNA and protein concurrently from the identical pattern at single-cell decision. The Tapestri Platform is being utilized by clients at main analysis facilities, pharmaceutical, and diagnostics firms worldwide to develop therapies and ultimately cures for most cancers. To study extra, go to missionbio.com.
Media Contact
Consort Companions for Mission Bio
[email protected]
SOURCE Mission Bio
Associated Hyperlinks
— to www.prnewswire.com
